搜索
Search
Search
/
/
/
The National Digestive Endoscopy Technology Conversion and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum was held in Shanghai
Check category

The National Digestive Endoscopy Technology Conversion and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum was held in Shanghai

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-04-17 11:36
  • Views:0

(Summary description)The National Digestive Endoscopy Technology Transformation and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum will be held in Shanghai Xijiao Hotel Conference Center on April 8-10, 2021

The National Digestive Endoscopy Technology Conversion and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum was held in Shanghai

(Summary description)The National Digestive Endoscopy Technology Transformation and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum will be held in Shanghai Xijiao Hotel Conference Center on April 8-10, 2021

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-04-17 11:36
  • Views:0
Information

April 8-10, 2021

The National Digestive Endoscopy Technology Transformation and Gastrointestinal Tumor Prevention and Control Strategy Summit Forum was held. The conference invited academicians and experts engaged in tumor-related research and medical device research and development, clinicians engaged in the first-line diagnosis and treatment of digestive endoscopy, and domestic digestive endoscopy research and development companies Participate together to conduct academic reports and discussions on key issues that promote the transformation of digestive endoscopy technology into digestive tract tumor prevention and control in my country.

 

The theme of this conference is:

Do not forget the original intention, keep the mission in mind, and move forward to eliminate gastrointestinal cancer.

Speech by Academician Li Zhaoshen

 

Academician Li Zhaoshen: Gastrointestinal cancer is most worthy of early screening, and it should be the earliest screening.

 

Professor Li Zhaoshen, academician of the Chinese Academy of Engineering, director of the Department of Gastroenterology, the First Affiliated Hospital of Naval Military Medical University (Shanghai Changhai Hospital), and director of the National Center for Clinical Research of Digestive Diseases, pointed out that the high incidence of colorectal cancer in my country poses a serious threat to people's health.

 

According to the 2015 Cancer Report, there were 4.292 million new cases of malignant tumors nationwide, 2.512 million males and 1.78 million females, with an average of more than 12,000 new cases per day, and an average of more than 7,500 tumor deaths per day. Among them, the incidence and death of gastrointestinal tumors account for more than one-third of all cancers, which is close to half of the country. It is a big mountain that oppresses the health of the people. In 2020, the cost of malignant tumor treatment is expected to reach 1.5 trillion yuan, accounting for 1.7% of GDP, and the development trend is extremely severe.

 

In fact, gastrointestinal tumors can be screened out. Li Zhaoshen said that tumors are actually a chronic disease, and early screening can be treated with early intervention. For example, early screening of colorectal cancer will definitely be able to get a good treatment, because the development of colorectal cancer has been more than ten years, if polyps or precancerous lesions are found, resection can play a role in preventing colorectal cancer.

Li Zhaoshen, who prevents bowel cancer, said that cancer screening is not the goal, but cancer prevention is the goal. We hope that this year we can help 4000 county hospitals, help bring 10,000 specialist doctors, and be able to hold 1000 online academic activities, hoping to increase the early diagnosis rate of esophageal cancer, gastric cancer and colorectal cancer by 10% because of the base Very large, even if it is only 10%, it is incredible data. From an economic point of view, we can save 100 billion yuan. We hope that doctors engaged in the prevention and treatment of gastrointestinal cancer can work together to do a better job of screening for gastrointestinal cancer. Li Zhaoshen mentioned that it is recommended to use serological testing for preliminary gastric cancer screening, and then classify it according to the new gastric cancer screening scoring system, and then conduct targeted further screening.

 

BLOT bio

The service target of China Enterprise Dynamics is China's growing enterprises. They are characterized by a large number and a wide distribution, but the individual scale is small. The methods and methods of serological typing to detect HP
Using CagA and VacA standard protein antigens to detect the corresponding IgG antibodies in the serum of infected persons can be detected by immunoblotting, colloidal gold, ELISA and other immunological methods. Among them, Western blotting is more traditional, classic and reliable, and can be used as a confirmatory test.

 

Helicobacter pylori antibody typing detection kit (Western blotting)

This kit is used to qualitatively detect a variety of Helicobacter pylori (Hp) IgG antibodies in human serum in vitro, including cytotoxicity (CagA), vacuolation toxin (VacA) and urease subunit A (UreA) and B (UreB) antibodies . In addition to the diagnosis of Hp infection, it can also evaluate the virulence of the infected Hp, so as to guide doctors to adopt different treatment plans and implement the medical principles of precise diagnosis and treatment.

For several years, Burlaut has been deeply involved in the field of accurate diagnosis of Helicobacter pylori and completed the research project: "The biological characteristics and clinical application of CagA and VacA, the key pathogenic factors of Helicobacter pylori", which reveals that CagA and VacA are Helicobacter pylori The key pathogenic factor of H. pylori is of great significance to the precise diagnosis and treatment of Helicobacter pylori, and won the second prize of the National Science and Technology Progress Award.

 

Scan the QR code to read on your phone

© 202017.06.2019     >  Legal statement     >   Privacy statement      >  Contact us      粤ICP备11066943号

Copyright Shenzhen braute Biological Products Co., Ltd     Copyright @2020 ALL Rights Reserved     

Powered by www.300.cn